Cannabis arteritis mirrors thromboangiitis obliterans in its clinical and arteriographic presentation, but its relevant exposure is cannabis rather than tobacco.1 Whether cannabis arteritis is a subset of thromboangiitis obliterans or a unique pathologic entity is debatable. Delta-9-tetrahydrocannabinol, the primary psychoactive component of cannabis, is a peripheral vasoconstrictor.2 This offers mechanistic insight into how cannabis may…
Search results for: cannabis
Case Report: Atypical Presentation of Idiopathic Retroperitoneal Fibrosis
Retroperitoneal fibrosis (RPF) is a rare condition characterized by aberrant fibroinflammatory tissue developing in the retroperitoneum. This disorder was initially called Ormond’s disease. RPF may be idiopathic or secondary to other conditions. Idiopathic RPF is a part of the disease spectrum of chronic periaortitis due to its typical periaortoiliac localization. Idiopathic retroperitoneal fibrosis is a…
Getting Physical: Telemedicine & the Enduring Value of the Physical Exam
I have been tongue-tied, of late. When I was a medical student, I was told not to turn the physical examination into an aerobic workout. This sage piece of advice was imparted by my physical examination preceptor, who had watched me perform a complete examination on a hapless volunteer. At the time, I thought of…
Cannabinoids Show Potential in Pain Management
ATLANTA—The potential of cannabis‐based medicines is a hot topic, particularly as pain management therapy for arthritis and other conditions. However, confusion abounds regarding its therapeutic potential, how it can be administered and even the correct terminology to use. David P. Finn, PhD, professor of pharmacology and therapeutics, and founding co-director of the Centre for Pain…
Move Along: Insights Into Gastrointestinal Involvement in Systemic Sclerosis
For patients with gastrointestinal (GI) manifestations of scleroderma, the effect on quality of life & longevity can be dramatic. But advances are being made in the diagnosis & treatment of these patients…
Marijuana for Rheumatology Patients?
SAN DIEGO—What does cannabis offer to the treatment and management of rheumatology patients and the range of pain states they experience? What do we really know about its long-term effects? These are hard questions to answer with currently available data and a reality nuanced by complications cannabis advocates don’t always recognize, according to two experts…
Tips for Managing Young Adult Rheumatology Patients
Often, young adults (18–23 years old) with rheumatic illness demonstrate poor adherence to treatment regimens, lack advocacy skills and have inadequate knowledge about diagnosis and treatment.1 Patients presenting at a transition clinic are typically comfortable with having their parents continue to be centrally involved with their care, but this is a time in life when…
Would Legalizing Medical Marijuana Help Curb the Opioid Epidemic?
(Reuters Health)—In states that legalized medical marijuana, U.S. hospitals failed to see a predicted influx of pot smokers, but in an unexpected twist, they treated far fewer opioid users, a new study shows. Hospitalization rates for opioid painkiller dependence and abuse dropped on average 23% in states after marijuana was permitted for medicinal purposes, the…
Evidence Needed to Support Marijuana Use for Pain Relief in Rheumatologic Conditions
With the chronic pain and other health issues that many rheumatology patients face every day, it’s natural for rheumatologists and their patients to wonder if cannabinoid treatments are of any help. At this point, there is insufficient evidence to recommend cannabinoid treatments to manage rheumatic diseases, according to a review article published in the May…
Medical Marijuana’s Potential Benefits, Risks
CHICAGO—Despite the complicated politics surrounding medical marijuana, cannabis has a wide variety of medical benefits and potential benefits, but the risks need to be understood, said Daniel Clauw, MD, director of the Chronic Pain and Fatigue Research Center at the University of Michigan, in a session at the ACR’s 2016 State-of-the-Art Clinical Symposium. Effects It’s…